[{"address1": "1 Ashley Road", "address2": "3rd Floor", "city": "Altrincham", "zip": "WA14 2DT", "country": "United Kingdom", "website": "https://www.centessa.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.", "fullTimeEmployees": 76, "companyOfficers": [{"maxAge": 1, "name": "Dr. Saurabh  Saha M.D., Ph.D.", "age": 47, "title": "CEO & Director", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 1041809, "exercisedValue": 0, "unexercisedValue": 6715049}, {"maxAge": 1, "name": "Dr. David M. Chao Ph.D.", "age": 55, "title": "Chief Administrative Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 710304, "exercisedValue": 0, "unexercisedValue": 98467}, {"maxAge": 1, "name": "Mr. John J. Crowley CPA", "age": 49, "title": "CFO and Principal Financial & Accounting Officer", "yearBorn": 1974, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tia L. Bush", "age": 52, "title": "Chief Technology & Quality Officer", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kristen K. Sheppard Esq., J.D.", "title": "Senior Vice President of Investor Relations & Corporate Communications", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Iqbal J. Hussain L.L.B.", "age": 42, "title": "General Counsel, Chief Compliance Officer & Corporate Secretary", "yearBorn": 1981, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karen M. Anderson", "age": 55, "title": "Chief People Officer", "yearBorn": 1968, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Gregory M. Weinhoff M.B.A., M.D.", "age": 52, "title": "Chief Business Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 655004, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mario Alberto Accardi Ph.D.", "title": "President of the Orexin Program", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. April  Dovholuk", "title": "Senior Vice President of Development Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 17.5, "open": 17.79, "dayLow": 15.95, "dayHigh": 17.79, "regularMarketPreviousClose": 17.5, "regularMarketOpen": 17.79, "regularMarketDayLow": 15.95, "regularMarketDayHigh": 17.79, "forwardPE": -10.282777, "volume": 725609, "regularMarketVolume": 725609, "averageVolume": 632501, "averageVolume10days": 638990, "averageDailyVolume10Day": 638990, "bid": 15.95, "ask": 16.05, "bidSize": 100, "askSize": 100, "marketCap": 2109520000, "fiftyTwoWeekLow": 5.583, "fiftyTwoWeekHigh": 18.74, "priceToSalesTrailing12Months": 307.8243, "fiftyDayAverage": 15.867, "twoHundredDayAverage": 11.6326, "currency": "USD", "enterpriseValue": 1591694336, "floatShares": 78521373, "sharesOutstanding": 128569000, "sharesShort": 2147348, "sharesShortPriorMonth": 1956095, "sharesShortPreviousMonthDate": 1727654400, "dateShortInterest": 1730332800, "sharesPercentSharesOut": 0.0167, "heldPercentInsiders": 0.01358, "heldPercentInstitutions": 0.92379, "shortRatio": 6.28, "shortPercentOfFloat": 0.020599999, "impliedSharesOutstanding": 131845000, "bookValue": 4.294, "priceToBook": 3.7261293, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -161264992, "trailingEps": -1.52, "forwardEps": -1.71, "enterpriseToRevenue": 232.262, "enterpriseToEbitda": -9.868, "52WeekChange": 1.4857955, "SandP52WeekChange": 0.31793165, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "CNTA", "underlyingSymbol": "CNTA", "shortName": "Centessa Pharmaceuticals plc", "longName": "Centessa Pharmaceuticals plc", "firstTradeDateEpochUtc": 1622208600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "9f3bdf1d-ddc8-3bbd-88f7-8fed1cc82ba8", "messageBoardId": "finmb_704505677", "gmtOffSetMilliseconds": -18000000, "currentPrice": 16.0, "targetHighPrice": 35.0, "targetLowPrice": 22.0, "targetMeanPrice": 27.71429, "targetMedianPrice": 27.0, "recommendationMean": 1.25, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 7, "totalCash": 518448992, "totalCashPerShare": 4.46, "ebitda": -161299008, "totalDebt": 75700000, "totalRevenue": 6853000, "debtToEquity": 15.166, "revenuePerShare": 0.065, "returnOnAssets": -0.20471, "returnOnEquity": -0.42521, "grossMargins": 1.0, "operatingMargins": -23.58865, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-11-15"}]